The Endometriosis market is expected to experience substantial growth between 2020 and 2034, according to the latest DelveInsight report, “Endometriosis Market Insights, Epidemiology, and Market Forecast, 2034.” This anticipated growth is driven by advancements in existing therapies and the introduction of new treatments scheduled for launch between 2023 and 2034, alongside an incremental increase in incidence rates.
The report provides a comprehensive overview of current treatment practices for Endometriosis, details upcoming drugs in the pipeline, and analyzes the market shares of various therapies. It also projects the market size trajectory from 2020 to 2034 across the 7MM, which includes the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan.
Key highlights from the Endometriosis market report:
-
In 2023, the endometriosis market across the 7MM was valued at approximately USD 2,300 million. Prescription analgesics, including NSAIDs and opioids, currently hold the largest market share and are expected to continue leading throughout the forecast period.
-
Within this market, the United States represented the largest share, with a market size of around USD 1,400 million in 2023. In the EU4 and the UK region, the UK held the highest market share at approximately 20%, while Spain had the smallest share.
-
Market growth is primarily driven by the anticipated launch of pipeline treatments such as OG-6219 and the combination of elagolix with estradiol and norethindrone during the forecast period from 2024 to 2034.
-
Endometriosis is categorized into one of four stages based on the extent of endometrial implants outside the uterus: Stage 1 (minimal implants), Stage 2 (mild implants), Stage 3 (moderate implants), and Stage 4 (severe implants), which is characterized by numerous deep implants and extensive adhesions.
-
Certain factors increase the likelihood of developing endometriosis, including not having children, early onset of menstruation, late menopause, short menstrual cycles, a family history of the condition (e.g., mother, aunt, or sister with endometriosis), and disorders of the reproductive tract.
-
Patients often experience a diagnostic delay of approximately 6–10 years, primarily due to delays in referrals from primary care to specialists.
-
In 2023, there were approximately 10,770,000 diagnosed cases of endometriosis across the 7MM. Among these, moderate cases represented the largest proportion at around 40%, followed by severe and mild cases.
-
The total market size for endometriosis in the 7MM was USD 2,300 million in 2023 and is anticipated to grow substantially over the forecast period, driven by the introduction of new therapies.
-
Current pharmacological treatments have limitations: hormone therapy may impact fertility, NSAIDs are often used off-label for pain management and may cause kidney damage with chronic use, and opioids carry a high risk of addiction.
-
New therapies under development aim to address these limitations. Notable emerging treatments include OG-6219 (Organon), linzagolix (ObsEva SA), HMI-115 (Hope Medicine), and VML-0501 (Viramal). OG-6219 is expected to capture the largest market share by 2034.
-
The endometriosis market's growth is anticipated to be driven by the entry of novel therapies with improved clinical profiles, increased research and development, and a deeper understanding of the disease. The rise in market size from 2020 to 2034 will be fueled by both existing treatments like NSAIDs and opioids and new pipeline candidates such as OG-6219 and elagolix combined with estradiol and norethindrone.
Driving Forces Behind the Endometriosis Market Growth
The significant growth of the Endometriosis market is driven by a combination of factors, including innovations in therapy, shifting demographic trends, and evolving treatment approaches.
Discover the Anticipated Evolution and Growth of the Market @ Endometriosis Therapeutics Market Forecast
Therapeutic Advancements and Emerging Treatments:
-
Endometriosis Clinical Trial Progression: The market is poised for substantial growth, fueled by the development of new therapies anticipated to launch between 2023 and 2034. Leading companies such as AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, and others are actively working on innovative drugs aimed at entering the market.
-
Endometriosis Innovative Therapies: Ongoing research and development are driving the introduction of innovative therapies for addressing the signs and symptoms of Endometriosis. Treatments like ORILISSA (elagolix) and MYFEMBREE (relugolix, estradiol, and norethindrone acetate), among others, are significantly impacting the Endometriosis market.
Endometriosis Epidemiological Trends and Patient Demographics:
· Increasing Prevalence and awareness: The rising incidence of Endometriosis is influenced by factors such as lifestyle changes. These factors contribute to an expanding patient pool, creating a growing market for pharmaceuticals and treatments related to Endometriosis.
-
Global Prevalence: Endometriosis impacts approximately 1 in 10 women of reproductive age around the world.
-
Age of Onset: Symptoms generally start during a woman's reproductive years, commonly between ages 25 and 40, though it can also affect younger individuals.
-
Delayed Diagnosis: Diagnosis is frequently delayed due to the wide range of symptoms and the common misconception that severe menstrual pain is normal, which contributes to an underestimation of the condition's prevalence.
Request for a sample page @ https://www.delveinsight.com/sample-request/endometriosis-market
Leading Endometriosis Companies and Emerging Drugs: Leading companies including AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, and Organon are actively engaged in developing innovative drugs for potential introduction into the Endometriosis market.
Endometriosis Therapeutic Landscape: Notable therapies for the treatment of Endometriosis include ORILISSA (elagolix), MYFEMBREE (relugolix, estradiol, and norethindrone acetate), among others.
Endometriosis Overview:
Endometriosis is a condition characterized by the presence of endometrial tissue outside the uterine cavity, which causes recurrent bleeding due to the hormonal responsiveness of this ectopic tissue, leading to fibrosis. Commonly affecting adolescents and women of reproductive age, endometriosis is associated with chronic pelvic pain and infertility. The most frequent sites for endometriosis include the ovaries, pelvic peritoneum, uterosacral ligaments, and torus uterinus. It can also occur in atypical locations such as the cervix, round ligaments, ureter, and nerves, and in rare cases, it may affect extrapelvic sites like the upper abdomen, subphrenic fold, or abdominal wall.
Diagnosing endometriosis can be challenging due to its nonspecific symptoms. A detailed patient history and a comprehensive evaluation of pain are essential. A stepwise pelvic examination may uncover anatomical features indicative of endometriotic implants, and imaging techniques, can provide additional insight.
Laparoscopy: This procedure allows direct visualization of endometriosis, revealing peritoneal implants, peritoneal windows, endometriomas, and deep infiltrating nodules, often accompanied by adhesions.
Imaging: While imaging techniques like ultrasound, MRI, and CT scans can assist in diagnosis, they have limitations. Ultrasound is accessible and inexpensive but dependent on operator skill; MRI offers more accuracy but is more costly; CT scans are less useful for visualizing pelvic organs.
Serum Markers: There is ongoing research into serum markers for diagnosing endometriosis, monitoring disease activity, and assessing treatment response. Investigated markers include cytokines, matrix metalloproteinases, adhesion molecules, and indicators of angiogenesis or inflammation.
Endometrial Nerve Fibers: Endometrial biopsies are being studied for diagnosis, with recent research showing an increased presence of nerve fibers in the endometrium of women with endometriosis compared to those without.
Current treatment strategies focus on surgical removal of endometriotic lesions via laparoscopy, which can alleviate pain and improve pregnancy rates, and pharmacological therapies aimed at suppressing pain, ovarian function, and estrogen action. However, endometriosis often recurs, with estimates indicating that 21.5% of patients experience recurrence within 2 years and 40–50% within 5 years of surgery. As a result, many patients undergo multiple surgeries and/or long-term pharmacological treatment during their reproductive years.
Available therapies include oral contraceptives (off-label), progestins as a first-line treatment, and GnRH agonists/antagonists as a second-line option. While effective, GnRH agonists/antagonists induce hypoestrogenism and can lead to significant side effects like menopause and osteoporosis. These treatments also impact fertility. Persistent pain, a common and debilitating symptom, is often managed with NSAIDs, which may have variable efficacy and potential long-term side effects. There is a critical need for new non-hormonal treatments to address the limitations of current options for endometriosis.
Endometriosis Epidemiology Segmentation:
-
In 2023, the total number of diagnosed prevalent cases of endometriosis across the 7MM (United States, EU4, and Japan) was approximately 10.8 million.
-
The United States recorded the highest number of these cases. Within the 7MM, moderate cases represented the largest share of diagnosed prevalent cases by pain severity.
-
Endometriosis is most prevalent among women aged 18-29, accounting for around 40% of all prevalent cases in the 7MM. In the US alone, approximately 2.9 million cases of endometriosis were treated in 2023, with the UK and France following in prevalence.
The Endometriosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
• Total Prevalence of Endometriosis
• Prevalent Cases of Endometriosis by severity
• Gender-specific Prevalence of Endometriosis
• Diagnosed Cases of Endometriosis
Endometriosis Market Outlook
Currently, there is no cure for endometriosis; treatments focus on managing symptoms such as pain and infertility. These treatments include drug therapies, both analgesic and hormonal, as well as surgical options. While drug therapies can alleviate pain, surgery remains the only option shown to improve fertility rates. Existing treatment guidelines for endometriosis prioritize pain management and addressing infertility, recommending the use of nonsteroidal anti-inflammatory drugs (NSAIDs), combined hormonal contraceptives, progestogens (or antiprogestogens), gonadotropin-releasing hormone (GnRH) agonists and antagonists, as well as surgical approaches such as fulguration or excision of endometrial lesions, or hysterectomy with or without bilateral salpingo-oophorectomy.
New therapeutic agents with innovative mechanisms are under development by companies such as ObsEva SA, Myovant Sciences, Hope Medicine, and Organon. These include LHRH receptor antagonists, gonadotropin-releasing hormone stimulants, and prolactin receptor antagonists, among others.
In summary, although current treatments do not provide a complete solution, the development of new therapies with novel mechanisms holds promise for addressing significant unmet needs in endometriosis management. As new treatments become available and healthcare spending increases across the 7MM, the treatment landscape for endometriosis is expected to experience substantial growth during the forecast period from 2024 to 2034.
Endometriosis Marketed Therapies
-
ORILISSA (elagolix): AbbVie
-
MYFEMBREE (relugolix, estradiol, and norethindrone acetate): Myovant/Pfizer
Endometriosis Emerging Therapies
-
ORIAHNN (elagolix/estradiol/norethindrone acetate): AbbVie/Neurocrine Biosciences
-
Linzagolix (OBE2109): ObsEva/Kissei Pharmaceuticals
DelveInsight's comprehensive report provides a thorough exploration of the Endometriosis market, covering key players, emerging therapies, treatment dynamics, and market challenges.
For in-depth insights, access the full report @ Endometriosis Market Outlook 2034
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
